<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> is still a frequent cause of morbidity and mortality in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients receiving chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Recently the main cause of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> has changed from <z:mp ids='MP_0001795'>gram-negative</z:mp> to <z:mp ids='MP_0001796'>gram-positive</z:mp> bacteria and the resistance to antibiotics has increased </plain></SENT>
<SENT sid="2" pm="."><plain>This study aimed to access the effectiveness of antimicrobial prophylaxis (AP) with orally absorbable antibiotics </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Ninety-five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients receiving chemotherapy at Catholic Hemopoietic Stem Cell Transplantation Center from March 1999 to July 1999 were randomly divided into the AP group (250 mg ciprofloxacin twice a day, 150 mg <z:chebi fb="0" ids="32109">roxithromycin</z:chebi> twice a day, 50 mg <z:chebi fb="2" ids="46081">fluconazole</z:chebi> once a day) and the control group for a prospective analysis </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The incidence of <z:hpo ids='HP_0001945'>fever</z:hpo> was 82.6% in the AP group and 91.6% in the control group (p = 0.15) </plain></SENT>
<SENT sid="5" pm="."><plain>Though classification and sites of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> showed no difference between the two groups, the catheter associated <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> occurred more frequently in the AP group in significance </plain></SENT>
<SENT sid="6" pm="."><plain>The time interval between initiation of chemotherapy and <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001945'>fever</z:hpo>, white blood cell (WBC) count at the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001945'>fever</z:hpo>, duration of <z:hpo ids='HP_0001882'>leukopenia</z:hpo> (WBC &lt; 1,000/mm3), duration of systemic antibiotic therapy, mortality due to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and hospitalization period from the data starting chemotherapy showed no differences between the two groups </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infections</z:e> due to <z:mp ids='MP_0001795'>gram negative</z:mp> bacteria decreased to 33.3% in the AP group (vs. 92% in the control group), but <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> due to <z:mp ids='MP_0001796'>gram positive</z:mp> bacteria increased to 66.7% (vs. 8% in the control group) </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0001795'>Gram negative</z:mp> bacteria showed 100% resistance to ciprofloxacin in the AP group and <z:mp ids='MP_0001796'>gram-positive</z:mp> bacteria showed 90-100% resistance to <z:chebi fb="2" ids="42355,48923">erythromycin</z:chebi>, regardless of the presence of AP </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The AP could not reduce the occurrence of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> or <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> associated <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients receiving chemotherapy </plain></SENT>
<SENT sid="10" pm="."><plain>On considering increased <z:mp ids='MP_0001796'>gram-positive</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and resistance to fluoroquinolone and <z:chebi fb="0" ids="25106">macrolide</z:chebi>, routine prescription of AP should be reconsidered </plain></SENT>
<SENT sid="11" pm="."><plain>Further studies that assess the effectiveness of AP in other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and bone marrow transplantation are required </plain></SENT>
</text></document>